Vanishing White Matter – eIF2B Mouse Models
Test novel vanishing white matter disease therapeutics with relevant models possessing mutations in genes encoding the eukaryotic translation initiation factor 2B (eIF2B)
eIF2B Mouse Models Key Characteristics
Leukodystrophies refer to a over 50 conditions characterised by extensive brain white matter degeneration. Vanishing white matter (VWM) disease is a rare and fatal leukodystrophy characterised by chronic and progressive motor dysfunction as well as mild cognitive decline. VWM is caused by recessive mutations in the five genes encoding the protein complex eukaryotic translation initiation factor 2B (eIF2B). VWM can be studied using eIF2B mouse models of VWM that have a genetic mutation in the same gene (eIF2B) that causes VWM in humans.
In line, eIF2B mouse models with homozygous point mutations in Eif2b5 and Eif2b4 that recapitulate the human VWM pathology form part of InnoSer’s rare genetic disease portfolio and expertise through a collaboration with the Amsterdam Leukodystrophy Center at Amsterdam UMC. VWM mutant mice show motor impairments, VWM-related alterations in mRNA expression, astrocyte and oligodendrocyte immaturity and dysfunction, and an immature myelin structure. The eIF2B mouse models have been extensively characterized (Dooves et al. 2016), with poof of concept intervention studies showing deregulated integrated stress response as a clear therapeutic target (Abbink et al. 2019).
✓ VWM mice have homozygous point mutations in eIFf2B4 or eIF2B5.
✓ VWM mice recapitulate motor symptoms that mimic those seen in humans with the disease, such as coordination problems. and tremors.
✓ VWM mice recapitulate cellular dysfunction seen in patients (e.g., deregulated ISR, astrocyte dysfunction).
Take advantage of InnoSer’s expertise, flexibility and collaborative approach for your research. We support our clients in identifying new drugs or applications, characterizing their pharmacological properties, and conducting safety and efficacy testing with state-of-the-art readout capabilities and histopathological analysis.
InnoSer’s neurology expert team possesses relevant experience in working with multiple therapy types ranging from small molecules, peptides, enzymes, oligonucleotides, and gene therapy (viral vectors – e.g.. AAVs).
C'est ici que commence votre recherche en neurologie.
Choisissez en toute confiance le modèle adapté à vos recherches
eIF2B Mouse Model Sample Data

eIF2B mutant mice show impairments in the Balance Beam test
The Balance Beam sensorimotor coordination test scores the ability of mice to traverse a stationary horizontal rod. Coordination of the mouse is measured by the latency to cross the beam and the number of foot slips made.
Vanishing White Matter (VWM) Mouse Models Readouts
Paramètres biologiques
Test the efficacy of your treatments with the following biological readouts:
- Histology (e.g., nestin/GFAP, S100B)
- RT-qPCR (ISR markers)
- Western blot (MBP)
Featured Publications
- Dooves, S., Bugiani, M., Postma, N. L., Polder, E., Land, N., Horan, S. T., van Deijk, A. L., van de Kreeke, A., Jacobs, G., Vuong, C., Klooster, J., Kamermans, M., Wortel, J., Loos, M., Wisse, L. E., Scheper, G. C., Abbink, T. E., Heine, V. M., & van der Knaap, M. S. (2016). Astrocytes are central in the pathomechanisms of vanishing white matter. The Journal of clinical investigation, 126(4), 1512–1524. https://doi.org/10.1172/JCI83908
- Abbink, T. E. M., Wisse, L. E., Jaku, E., Thiecke, M. J., Voltolini-González, D., Fritsen, H., Bobeldijk, S., Ter Braak, T. J., Polder, E., Postma, N. L., Bugiani, M., Struijs, E. A., Verheijen, M., Straat, N., van der Sluis, S., Thomas, A. A. M., Molenaar, D., & van der Knaap, M. S. (2019). Vanishing white matter: deregulated integrated stress response as therapy target. Annals of clinical and translational neurology, 6(8), 1407–1422. https://doi.org/10.1002/acn3.50826
Les personnes qui travaillent sur vos recherches

Sofie Carmans, docteure
Chercheur principal en neurologie

Thomas Vogels, docteur ès sciences
Chercheur principal en neurologie
Découvrez d'autres modèles de maladies génétiques rares pertinents
Découvrez les dernières recherches d'InnoSer
Accréditation AAALAC
InnoSer a obtenu l'accréditation AAALAC, ce qui témoigne de notre engagement en faveur d'une prise en charge et d'une utilisation responsables des animaux. AAALAC International est une organisation à but non lucratif qui promeut le traitement sans cruauté des animaux dans le domaine scientifique par le biais de programmes volontaires d'accréditation et d'évaluation. Notre accréditation est valable trois ans, y compris en 2023. Pour en savoir plus sur le programme d'accréditation AAALAC ici.
![]()
Bien-être animal
Les « 3R » ont une incidence sur tous les domaines, depuis les changements politiques et réglementaires jusqu’au développement et à l’adoption de nouvelles technologies et approches. C’est pourquoi InnoSer s’engage en permanence à suivre ces processus. Les mesures que nous mettons en œuvre optimisent notre capacité à remplacer, réduire et perfectionner l’utilisation des animaux et facilitent notre engagement envers ces principes dans le cadre de la recherche et du développement de médicaments.
info@innoserlaboratories.com
Liens rapides
















![Neurosciences translationnelles : profilage longitudinal complet des souris femelles et mâles porteurs de la mutation Tau[P301S]](https://www.innoserlaboratories.com/wp-content/uploads/2026/06/Female-TauP301S-mice-show-early-spontaneous-hyperactivity-in-automated-home-cages-PhenoTyperTM-229375_1080x323.png)

![Modèle murin Tau[P301S] dont la sensibilité au composé a été démontrée, destiné à la validation préclinique du concept](https://www.innoserlaboratories.com/wp-content/uploads/2026/03/Proven-Compound-susceptible-TauP301S-mouse-model-for-preclinical-proof-of-concept--1080x675.png)
